These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Jarmin S; Kymalainen H; Popplewell L; Dickson G Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293 [TBL] [Abstract][Full Text] [Related]
38. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910 [TBL] [Abstract][Full Text] [Related]
39. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model. Hawkes N BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900 [No Abstract] [Full Text] [Related]
40. New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Touznik A; Lee JJ; Yokota T Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]